After receiving a cease and desist from the FDA and getting slapped with a class action law suit, genetic testing startup 23andMe has announced via blog post that it will not complete health-related reports on kits purchased on or after November 22 — the date the FDA posted its complaint letter — until it’s reached regulatory approval. The company is offering a full refund to those who don’t have access to their genetic reports, as its unclear when (and how) the service will come back. 23andMe CEO Anne Wojcicki continues to stand by the accuracy of her company’s tests, and the firm continues to issue ancestry-related and raw-data reports.
It’s a big blow to the disruptive company, which has made a name for itself (and heavily advertised) its accuracy in identifying risk factors for diseases like cancer, Alzheimer’s and celiac disease. But it shows that regulations still apply to Silicon…
View original post 55 more words